Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | CA12 | O43570 | 2/20 | 0.49 |
| ▸ | CA1 | P00915 | 2/20 | 0.49 |
| ▸ | CA2 | P00918 | 2/20 | 0.49 |
| ▸ | CA9 | Q16790 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | CISD2 | Q8N5K1 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4568017 | 0.88 | GAA (0.50) | MEN1KMT2ANR1I2GAASMN1; SMN2 | |
| SCHEMBL11653044 | 0.85 | RAB9A (0.60) | RAB9ACA12CA1CA2CA9 | |
| SCHEMBL15145782 | 0.85 | ALDH1A1 (0.52) | RAB9ACA12CA1CA2CA9 | |
| SCHEMBL2589170 | 0.85 | ALDH1A1 (0.63) | RAB9AMEN1KMT2ANPC1GAA | |
| SCHEMBL31372038 | 0.85 | NPC1 (0.46) | RAB9AMEN1KMT2ANPC1NR1I2 | |
| SCHEMBL24253966 | 0.85 | POLB (0.56) | RAB9ACA12CA1CA2CA9 | |
| SCHEMBL2795277 | 0.85 | NPC1 (0.46) | RAB9AMEN1KMT2ANPC1NR1I2 | |
| SCHEMBL24150515 | 0.85 | NR1I2 (0.43) | RAB9ACA12CA1CA9MEN1 | |
| SCHEMBL7966118 | 0.84 | SMN1; SMN2 (0.52) | RAB9AMEN1KMT2ANPC1GAA | |
| SCHEMBL7665668 | 0.84 | KCNQ3 (0.46) | RAB9ACISD2GAASMN1; SMN2THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9061994-B1 | Materials and methods useful to induce vacuolization, cell death, or a combination thereof | THE UNIVERSITY OF TOLEDO (US) | 2015-06-23 | — | — | US | disclosed |
| US-20150152049-A1 | Materials And Methods Useful To Induce Vacuolization, Cell Death, Or A Combination Thereof | THE UNIVERSITY OF TOLEDO (US) | 2015-06-04 | — | — | US | disclosed |
| US-9023871-B2 | Materials and Methods Useful to Induce Vacuolization, Cell Death, or a Combination Thereof | THE UNIVERSITY OF TOLEDO (US) | 2015-05-05 | — | — | US | disclosed |
| US-20140213615-A1 | Materials and Methods Useful to Induce Vacuolization, Cell Death, or a Combination Thereof | THE UNIVERSITY OF TOLEDO (US) | 2014-07-31 | — | — | US | disclosed |
| US-8492560-B2 | Quinazoline derivatives as angiogenesis inhibitors | ASTRAZENECA AB (SE) | 2013-07-23 | — | — | US | disclosed |
| US-20120197027-A1 | Quinazoline Derivatives as Angiogenesis Inhibitors | STOKES ELAINE S E (GB) | 2012-08-02 | — | — | US | disclosed |
| EP-2341045-A1 | [[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-(phenylmethyl)-11H-indol-4-yl]oxy]acetic acid (acyloxy)alkyl or ((alkoxycarbonyl)oxy)alkyl ester as SPLA2 inhibitor | Eli Lilly and Company (US) | 2011-07-06 | — | — | EP | disclosed |
| WO-2010030727-A1 | 3-SUBSTITUTED-1H-INDOLE, 3-SUBSTITUTED-1H-PYRROLO[2,3-B]PYRIDINE AND 3-SUBSTITUTED-1H-PYRROLO[3,2-B]PYRIDINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH LLC (US) | 2010-03-18 | — | — | WO | disclosed |
| US-20100061982-A1 | 3-SUBSTITUTED-1H-INDOLE, 3-SUBSTITUTED-1H-PYRROLO[2,3-B]PYRIDINE AND 3-SUBSTITUTED-1H-PYRROLO[3,2-B]PYRIDINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH (US) | 2010-03-11 | — | — | US | disclosed |
| US-20100061982-A1 | 3-SUBSTITUTED-1H-INDOLE, 3-SUBSTITUTED-1H-PYRROLO[2,3-B]PYRIDINE AND 3-SUBSTITUTED-1H-PYRROLO[3,2-B]PYRIDINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH (US) | 2010-03-11 | — | — | US | disclosed |
| US-5919810-A | SEPTIC SHOCK | ELI LILLY AND COMPANY (US) | 1999-07-06 | — | — | US | disclosed |
| US-5919943-A | INHIBITION OF SPLA2 | ELI LILLY AND COMPANY (US) | 1999-07-06 | — | — | US | disclosed |
| EP-0620214-B1 | 1H-indole-3-acetic acid hydrazide sPLA2 inhibitors | LILLY CO ELI (US) | 1999-03-03 | — | — | EP | disclosed |
| US-5733923-A | SECRETORY PANCREATIC PHOSPHOLIPASE A2 | ELI LILLY AND COMPANY (US) | 1998-03-31 | — | — | US | disclosed |
| US-5684034-A | INHIBITORS OF HUMAN NON-PANCREATIC SECRETORY PHOSPHOLIPASE A2, TREATMENT OF SEPTIC SHOCK, TRAUMA, RESPIRATORY DISORDERS, RHEUMATIC ARTHRITIS, INHIBITORS OF ARACHIDONIC ACID RELEASE | ELI LILLY AND COMPANY (US) | 1997-11-04 | — | — | US | disclosed |
| US-5654326-A | SEPTIC SHOCK; HUMAN NONPANCREATIC SECRETORY PHOSPHOLIPASE | ELI LILLY AND COMPANY (US) | 1997-08-05 | — | — | US | disclosed |
| US-5578634-A | SEPTIC SHOCK TREATMENT | ELI LILLY AND COMPANY (US) | 1996-11-26 | — | — | US | disclosed |
| EP-0675110-A1 | 1H-Indole-3-glyoxylamide sPLA2 inhibitors | ELI LILLY AND COMPANY (US) | 1995-10-04 | — | — | EP | disclosed |
| EP-0620215-A1 | 1H-indole-3-acetamide derivatives as sPLA2 inhibitors | ELI LILLY AND COMPANY (US) | 1994-10-19 | — | — | EP | disclosed |
| EP-0620214-A1 | 1H-indole-3-acetic acid hydrazide sPLA2 inhibitors | ELI LILLY AND COMPANY (US) | 1994-10-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152049-A1 | Materials And Methods Useful To Induce Vacuolization, Cell Death, Or A Combination Thereof | BECN1, BAD, BAX | RAB9A 1669/4885CA12 1557/4885CA1 2026/4885 |
| US-20140213615-A1 | Materials and Methods Useful to Induce Vacuolization, Cell Death, or a Combination Thereof | BECN1, BAD, BAX | RAB9A 1669/4885CA12 1557/4885CA1 2026/4885 |
| US-20120197027-A1 | Quinazoline Derivatives as Angiogenesis Inhibitors | VEGFA, FLT1, KDR | RAB9A 225/4885CA12 1571/4885CA1 1051/4885 |
| US-20100061982-A1 | 3-SUBSTITUTED-1H-INDOLE, 3-SUBSTITUTED-1H-PYRROLO[2,3-B]PYRIDINE AND 3-SUBSTITUTED-1H-PYRROLO[3,2-B]PYRIDINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | MTOR, PDPK1, RICTOR | RAB9A 697/4885CA12 4302/4885CA1 2715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.